GSK's Twice-Yearly Depemokimab Reduces Nasal Polyp Size, Goes Under FDA Review

On Monday, the Food and Drug Administration (FDA) accepted for review GSK plc’s (NYSE:GSK) marketing application for depemokimab in two indications. The company released topline data from the trials in October 2024. The proposed indications are as add-on maintenance treatment of asthma in adult…